Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and ...

The primary end point, major pathologic response (MPR), was reviewed per consensus criteria and centrally confirmed: In the monotherapy arm, the MPR rate was 33.3%, with all responses being pathologic ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...

Inflammation fuels the high rate of cancer in people over 50, researchers find, leading them to test anti-inflammatories like ...

Adding dostarlimab to platinum-based chemotherapy and niraparib improved PFS in patients with advanced ovarian cancer.

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with ...

Researchers are beginning to wonder whether blockbuster drugs such as Wegovy, Ozempic and Zepbound could play a role in ...

The discontinued drug belongs to a class of ... which was being tested in combination with GSK's dostarlimab for treating advanced non-small cell lung cancer (NSCLC), did not demonstrate ...

Researchers at Memorial Sloan Kettering Cancer Center gave the drug dostarlimab to 117 patients who have tumors that carry mismatch repair mutations, a rare condition that accounts for about 2% to 3% ...